ArticleAnais brasileiros de dermatologia
Melanoma: tumor microenvironment and new treatments.
Article in Anais brasileiros de dermatologia. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Stabilized iRGD modification enhances NY-ESO-1 TCR-T infiltration in solid tumors and synergizes with PD-1 blockade.Cancer immunology, immunotherapy : CII · 2025Article
- Extracellular Matrix as a Target in Melanoma Therapy: From Hypothesis to Clinical Trials.Cells · 2024Review
- Emerging prospects of mRNA cancer vaccines: mechanisms, formulations, and challenges in cancer immunotherapy.Frontiers in immunology · 2024Review
- Comparison of chitosan nanoparticles containing Lippia citriodora essential oil and citral on the induction of apoptosis in A375 melanoma cells.BMC complementary medicine and therapies · 2023Article
- Oxidative Stress and Immune Response in Melanoma: Ion Channels as Targets of Therapy.International journal of molecular sciences · 2023Review
- Ubiquitination-related biomarkers in metastatic melanoma patients and their roles in tumor microenvironment.Frontiers in oncology · 2023Article
- Acute inflammatory reaction during anti-angiogenesis therapy combined with immunotherapy as a possible indicator of the therapeutic effect: Three case reports and literature review.Frontiers in oncology · 2023Review
- Identification of a novel immune-related gene signature for prognosis and the tumor microenvironment in patients with uveal melanoma combining single-cell and bulk sequencing data.Frontiers in immunology · 2023Article
- Review
- Comprehensive analysis: Necroptosis-related lncRNAs can effectively predict the prognosis of glioma patients.Frontiers in oncology · 2022Article
- Metabolic rewiring directs melanoma immunology.Frontiers in immunology · 2022Review
- Comprehensive analysis identifies IFI16 as a novel signature associated with overall survival and immune infiltration of skin cutaneous melanoma.Cancer cell international · 2021Article
- Carboplatin activates the cGAS-STING pathway by upregulating the TREX-1 (three prime repair exonuclease 1) expression in human melanoma.Bioengineered · 2021Article
- ESDN inhibits melanoma progression by blocking E-selectin expression in endothelial cells via STAT3.Cancer letters · 2021Article
- An Immune-Related lncRNA Signature to Predict Survival In Glioma Patients.Cellular and molecular neurobiology · 2021Article
- Development of an immune-related gene pairs index for the prognosis analysis of metastatic melanoma.Scientific reports · 2021Article
- Decoding Immune Heterogeneity of Melanoma and identifying immune-prognostic hub genes.Journal of Cancer · 2021Article
- Development and Validation of an Immune-Related Long Non-coding RNA Prognostic Model in Glioma.Journal of Cancer · 2021Article
- ERBB1/2/3 Expression, Prognosis, and Immune Infiltration in Cutaneous Melanoma.Frontiers in genetics · 2021Article
- DNA Damage Repair in Brain Tumor Immunotherapy.Frontiers in immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the recent past years, many discoveries in the tumor microenvironment have led to changes in the management of melanoma and it is rising up hopes, specially, to those in advanced stages. FDA approved seven new drugs from 2011 to 2014. They are: Vemurafenib, Dabrafenib and Trametinib, kinases inhibitors used for patients that have BRAFV600E mutation; Ipilimumab (anti-CTLA4), Pembrolizumab (anti-PD-1) and Nivolumab (anti-PD-1), monoclonal antibodies that stimulate the immune system; and Peginterferon alfa-2b, an anti-proliferative cytokine used as adjuvant therapy. In this article, we will review the molecular bases for these new metastatic melanoma therapeutic agents cited above and also analyze new molecular discoveries in melanoma study, as Cancer-Testis antigens (CT). They are capable of induce humoral and cellular immune responses in cancer patients and because of this immunogenicity and their restrict expression in normal tissues, they are considered an ideal candidate for vaccine development against cancer. Among CT antigens, NY-ESO-1 is the best characterized in terms of expression patterns and immunogenicity. It is expressed in 20-40% of all melanomas, more in metastatic lesions than in primary ones, and it is very heterogeneous inter and intratumoral. Breslow index is associate with NY-ESO-1 expression in primary cutaneous melanomas, but its relation to patient survival remains controversial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.